

References

1. Saris-Baglama RN, Dewey CJ, Chisholm GB, et al. QualityMetric health outcomes™ scoring software 4.0: installation guide. QualityMetric Incorporated; 2010.
2. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values manual. EORTC; 2008.
3. Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. *Health Qual Life Outcomes*. 2003;1(1):1-6.
4. van Andel G, Bottomley A, Fosså SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. *Eur J Cancer*. 2008;44(16):2418-2424.
5. Westdorp H, Creemers JH, van Oort IM, et al. High health-related quality of life during dendritic cell vaccination therapy in patients with castration-resistant prostate cancer. *Front Oncol*. 2020;10:536700.
6. Nielsen TK, Højgaard M, Andersen JT, et al. Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: A single-arm phase II trial. *Transl Androl Urol*. 2017;6(3):517.
7. US Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: draft guidance for industry. FDA-2020-D-2303. 2021.
8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85(5):365-376.
9. Weis J, Tomaszewski KA, Hammerlid E, et al. International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12). *J Natl Cancer Inst*. 2017;109(5).
10. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3):199-208.